A Director at Lexicon Pharmaceuticals (NASDAQ: LXRX) is Buying Shares

By Carrie Williams

Yesterday, a Director at Lexicon Pharmaceuticals (LXRXResearch Report), Raymond Debbane, bought shares of LXRX for $474.7K.

This recent transaction increases Raymond Debbane’s holding in the company by 4.77% to a total of $13.63 million. In addition to Raymond Debbane, 3 other LXRX executives reported Buy trades in the last month.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.51 and a one-year low of $1.13.

Three different firms, including Citigroup and Gabelli, currently also have a Buy rating on the stock.

The insider sentiment on Lexicon Pharmaceuticals has been positive according to 10 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.

Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. It drug candidates include XERMELO, Sotagliflozin, LX2761, and LX9211. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.